% | $
Quotes you view appear here for quick access.


  • Mar 23, 2010 2:45 PM Flag

    Generex: Weak attempt to save face

    The facts as stated by Generex in response to the columnist Adam Feuerstein statements.

    .......FACT 1: A number of independent, peer-reviewed studies of Generex Oral-lyn(TM) have been published in journals including Diabetes Care. In addition, Generex Oral-lyn(TM) trial data has been presented.........

    Entirely inconsequential at any rate as the exposure Generex/Oral-lyn has received has done little for this company.

    .......FACT 2: Scientific data contradicts such statements, underscored by the U.S. Food & Drug Administration (FDA) stamp of approval on Generex Oral-lyn(TM) with its inclusion in the Treatment Investigational New Drug (IND) prog......

    Doesn't touch on the potential harmful long term effects to the buccal mucosa from sustained usage administered by 100mph jet blasts containing a skin thinning agent and other harmful substances used for efficient permeation yet to be studied or the yet to be demonstrated through phase III studies, a non inferiority to injected insulin as measured by acceptable HbA1c levels in a broad range of subjects.

    ........FACT 3: Pursuing regulatory approvals overseas is an ordinary course of action for biotech and pharma companies while the U.S. FDA process in ong........

    The response to not having yet recognized revenue from the product oral-lyn as outlined in SEC filings is a non issue for complaint.

    ........FACT 4: Multiple independent studies published in Diabetes Research and Clinical Practice, Diabetic Medicine and other journals demonstr.........

    Item number 4 presents a grey area entirely open to debate where both arguments have merit as do all the issues Generex demands a retraction of statements made and an apology.

    The demand made by Generex in today's pr amounts to little more than a weak attempt at saving face with shareholders and the professional community.

    SortNewest  |  Oldest  |  Most Replied Expand all replies